{"gene":"F2RL1","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":2007,"finding":"PAR2 activation sensitizes TRPA1 channels in DRG neurons via PLC-mediated hydrolysis of plasma membrane PIP2, relieving tonic PIP2 inhibition of TRPA1 and increasing TRPA1 currents; this mechanism contributes to inflammatory pain.","method":"Electrophysiology in HEK293 cells transfected with TRPA1 and DRG neurons; PLC inhibitors and antibody sequestration of PIP2; colocalization immunofluorescence","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (electrophysiology, pharmacological inhibition, PIP2 sequestration) in both heterologous and native systems; widely cited","pmids":["17571167"],"is_preprint":false},{"year":2014,"finding":"Cathepsin S acts as a biased agonist of PAR2 by cleaving at E56↓T57 (distinct from canonical trypsin cleavage at R36↓S37), exposing a novel tethered ligand that selectively couples PAR2 to Gαs/cAMP but not Ca2+ mobilization, β-arrestin recruitment, or ERK1/2 activation; Cat-S–activated PAR2 then stimulates TRPV4 and causes hyperalgesia via adenylyl cyclase/PKA.","method":"Cleavage-site mapping; cAMP assay; Ca2+ mobilization assay; β-arrestin recruitment assay; Xenopus oocyte TRPV4 functional assay; PAR2/TRPV4 knockout mice; in vivo paw inflammation model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical cleavage site identification plus multiple functional signaling readouts plus genetic knockout validation in vivo","pmids":["25118282"],"is_preprint":false},{"year":2014,"finding":"Cathepsin S cleaves PAR2 near the N-terminus to expose a novel tethered ligand sequence KVDGTS; mutation of the cathepsin S cleavage site prevents receptor activation by the protease while the hexapeptide KVDGTS retains PAR2 signaling activity.","method":"Protease cleavage assay; site-directed mutagenesis of PAR2 cleavage site; peptide functional assay in cells expressing PAR2","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 — cleavage-site mapping with mutagenesis and peptide reconstitution","pmids":["24964046"],"is_preprint":false},{"year":2013,"finding":"PAR1 and PAR2 form a stable heterodimer that exhibits constitutive internalization driven by PAR1 C-terminal tail sorting motifs; thrombin-activated PAR1-PAR2 heterodimers co-internalize, recruit β-arrestins to endosomes, and enhance cytoplasmic (not nuclear) β-arrestin-mediated ERK1/2 activation.","method":"BRET; immunofluorescence microscopy; co-immunoprecipitation; cells expressing receptors exogenously and endogenously; ERK1/2 activation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, BRET, and functional signaling assays; multiple orthogonal methods in one study","pmids":["23476015"],"is_preprint":false},{"year":2012,"finding":"PAR2 facilitates plasma membrane delivery of PAR4 by disrupting PAR4's ER-retention complex with β-COP1 and promoting interaction with chaperone 14-3-3ζ; PAR2-PAR4 heterodimerization was confirmed by intermolecular FRET, and PAR2 co-expression enhanced PAR4 glycosylation and signaling.","method":"FRET; co-immunoprecipitation; mutagenesis of PAR4 RXR ER-retention sequence; immunofluorescence; glycosylation analysis; signaling assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — structural mutagenesis plus FRET plus biochemical co-IP with multiple readouts","pmids":["22411985"],"is_preprint":false},{"year":2013,"finding":"In gastric smooth muscle cells, PAR2 couples to Gq, G13, and Gi1, stimulating PI hydrolysis (via Gαq/Gαi), Rho kinase activation (via Gα13), and biphasic contraction; PAR2-activated RhoA is subject to feedback inhibition via NF-κB–dependent release of PKA catalytic subunit, which phosphorylates RhoA at Ser188.","method":"PAR2/Gα siRNA knockdown; Gα minigene expression; pertussis toxin; dominant-negative mutants; Rho kinase activity assay; contractility assay; phospho-immunoblotting","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological perturbations with defined signaling readouts","pmids":["23825105"],"is_preprint":false},{"year":2022,"finding":"In colitis, PAR2 redistributes from the basolateral membrane of colonocytes to early endosomes; endosomal PAR2 assembles signaling complexes containing Gαq, Gαi, and β-arrestin; dynamin-2-dependent endocytosis is required for PAR2-evoked colonic inflammation and hyperalgesia.","method":"Knockin mice expressing PAR2-muGFP; immunostaining; RNAScope in situ hybridization; confocal microscopy; Dnm2 siRNA knockdown; dynamin inhibitors; cytokine release assays; mouse colitis models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — endogenous fluorescent reporter knockin mice plus genetic knockdown plus functional readouts; strong mechanistic evidence","pmids":["35110404"],"is_preprint":false},{"year":2015,"finding":"EPCR-dependent activation of PAR2 by the ternary TF-VIIa-Xa coagulation complex is required for LPS-induced expression of Pellino-1 and IRF8, thereby initiating an interferon-regulated gene expression program; mice lacking EPCR or PAR2 fail to mount this interferon response.","method":"Bone marrow-derived myeloid cell cultures; RAW264.7 cells; PAR2/EPCR knockout mice; LPS challenge in vivo; mRNA profiling","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo (dual KO) plus in vitro mechanistic validation","pmids":["25733582"],"is_preprint":false},{"year":2011,"finding":"Genetic epistasis in mouse skin demonstrates that PAR2 is a downstream effector of the serine protease CAP1/Prss8: transgenic overexpression of CAP1/Prss8 causes epidermal hyperplasia, ichthyosis, and skin inflammation that is completely abolished on a PAR2-null background.","method":"Transgenic mouse models (K14-CAP1/Prss8); PAR2-null background; histology; barrier function assays; cytokine measurement","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — clean genetic epistasis with complete rescue phenotype in vivo","pmids":["21245842"],"is_preprint":false},{"year":2017,"finding":"Activated protein C (aPC) signals through a PAR2/PAR3 heterodimer on regulatory T cells (CD4+FOXP3+) to restrict allogenic T-cell activation and expand Tregs, thereby ameliorating graft-vs.-host disease.","method":"PAR2/PAR3 knockout mice; Treg frequency measurement; allogeneic HSC transplantation model; humanized mouse model (NSG-AB°DR4)","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — genetic deletion of PAR2 and PAR3 with defined cellular phenotype; validated in humanized mouse model","pmids":["28827518"],"is_preprint":false},{"year":2022,"finding":"GPR97 allosterically activates CD177-associated membrane proteinase 3 (mPR3) within a macromolecular CD177/GPR97/PAR2/CD16b complex on neutrophils; mPR3 activation within this complex cleaves and activates PAR2, triggering inflammatory activation, ICAM-1/VCAM-1 upregulation, and endothelial dysfunction.","method":"Crystallography of GPR97 extracellular domain; deletion analysis; co-immunoprecipitation; functional neutrophil activation assays; PAR2 activation readouts","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structure of binding domain combined with deletion analysis and functional assays","pmids":["36302784"],"is_preprint":false},{"year":2020,"finding":"PAR2-induced ovarian cancer cell migration and invasion requires cooperative signaling through Gαq/11, Gα12/13, and β-arrestin1/2 (not Gαs or Gαi), leading to serial activation of Src kinases, EGFR transactivation, and downstream MEK-ERK1/2-FOS/MYC/STAT3-COX2; loss of any single pathway component abolishes motility.","method":"CRISPR-Cas9 knockouts of PAR2, Gα proteins, and β-arrestin1/2; pharmacological inhibitors; western blots; migration/invasion assays","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 — CRISPR genetic knockouts combined with pharmacological dissection of each pathway node","pmids":["33226635"],"is_preprint":false},{"year":2019,"finding":"Furin is the principal proprotein convertase that cleaves PAR2 at Arg36↓; N-glycosylation of PAR2 at Asn30 reduces the efficiency but enhances selectivity of Furin cleavage; Furin expression enhances neuronal cell viability against PAR2-induced cytotoxicity in the context of HIV-1 infection.","method":"In vitro cleavage assays; site-directed mutagenesis of PAR2 (Arg36, Asn30); co-culture of neuroblastoma cells with HIV-1-infected macrophages; PACS1 trafficking studies","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 — biochemical cleavage assay with mutagenesis; functional validation in neuronal co-culture model","pmids":["30683917"],"is_preprint":false},{"year":2015,"finding":"PAR2 deficiency in mice (PAR-2 knockout) prevents PAR1-dependent pro-fibrotic responses in bleomycin-induced pulmonary fibrosis; PAR1 signaling in fibroblasts requires the presence of PAR2, establishing PAR2 as necessary for PAR1-dependent signaling in this context.","method":"PAR2-knockout mice; bleomycin lung fibrosis model; fibroblast stimulation with PAR1/PAR2 agonists; PAR1 antagonist (P1pal-12); collagen/SMA western blot; hydroxyproline quantification","journal":"Journal of cellular and molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout plus pharmacological epistasis in vivo and in vitro","pmids":["25689283"],"is_preprint":false},{"year":2020,"finding":"The PAR2 inhibitor I-287 acts as a negative allosteric modulator selectively blocking Gαq and Gα12/13 signaling and their downstream effectors while having no effect on Gi/o signaling or β-arrestin2 engagement; selective inhibition of only the Gαq/Gα12/13 pathways is sufficient to block PAR2-driven inflammation in vivo.","method":"BRET-based signaling pathway profiling; in vivo inflammatory model; selective PAR2 inhibitor characterization","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 2 — multi-pathway BRET profiling plus in vivo validation with defined selectivity","pmids":["33247181"],"is_preprint":false},{"year":2022,"finding":"PAR2 activation downregulates the hepatic glucose transporter GLUT2 through a Gq-MAPK-FoxA3 pathway and inhibits insulin-Akt signaling through a Gq-calcium-CaMKK2 pathway, thereby suppressing glucose internalization and glycogen storage; liver-specific PAR2 knockout rescues these defects.","method":"Whole-body and liver-specific PAR2-KO mice; mechanistic pathway inhibitors; GLUT2/FoxA3 expression assays; Akt phosphorylation assays; glycogen storage measurements; pepducin therapeutic dosing","journal":"Hepatology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific genetic knockout plus pharmacological dissection of bifurcating signaling pathways","pmids":["35603482"],"is_preprint":false},{"year":2019,"finding":"PAR2 deficiency in mice reduces plasma and total liver cholesterol by ~50% through decreased expression of hepatic cholesterol synthesis genes and induction of reverse cholesterol transport; Gi-Jnk1/2 signaling downstream of PAR2 was identified as the key effector pathway regulating lipid and cholesterol homeostasis in liver.","method":"PAR2-KO mice (C57BL/6 F2rl1-/-); normal/high-fat diet feeding; plasma/liver lipid assays; hepatic gene expression; fecal bile acid output; pathway inhibitor studies","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with multi-parameter metabolic phenotyping and pathway identification","pmids":["31668396"],"is_preprint":false},{"year":2017,"finding":"PAR2 expression is required for TGF-β1-induced ERK1/2 activation (but not SMAD activation) and cell migration; PAR2 physically interacts with ALK5 (TGF-β type I receptor) as shown by co-immunoprecipitation, and ERK inhibition abolishes PAR2-AP- and TGF-β1-induced migration.","method":"siRNA depletion of PAR2; xCELLigence cell migration assay; phospho-immunoblotting for ERK1/2 and SMAD; co-immunoprecipitation of PAR2 with ALK5; MEK inhibitor U0126","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP interaction plus siRNA knockdown with functional migration readout; single lab","pmids":["29261154"],"is_preprint":false},{"year":2002,"finding":"TF/FVIIa complex mediates vascular smooth muscle cell migration via PAR2; PAR2-activating peptide SLIGKV (but not PAR1-AP or PAR4-AP) stimulates SMC migration comparable to TF/FVIIa, and anti-PAR2-AP antisera blocks TF/FVIIa-induced migration.","method":"Modified Boyden chamber migration assay; PAR2-activating peptide; neutralizing antisera; immunostaining of human coronary arteries","journal":"Thrombosis research","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional migration assay with pharmacological blockade; single lab","pmids":["12479889"],"is_preprint":false},{"year":2008,"finding":"PAR2 triggers IL-8 release from GI epithelial cells via two independent, non-overlapping signaling pathways: MEK/ERK and PI3-kinase/Akt; inhibition of MEK blocks ERK but not Akt phosphorylation, and vice versa.","method":"PAR2-activating peptide stimulation; MEK inhibitor U0126; PI3K inhibitor LY294002; ERK and Akt phosphorylation by immunoblot; IL-8 ELISA","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological pathway dissection with dual independent signaling readouts","pmids":["18854173"],"is_preprint":false},{"year":2014,"finding":"PAR2 activation reduces cytokine-induced epithelial apoptosis via concurrent stimulation of MEK1/2 (leading to BAD phosphorylation at Ser112) and PI3K (leading to BAD phosphorylation at Ser136); simultaneous inhibition of both pathways is required to abolish the anti-apoptotic effect; PAR2 siRNA knockdown eliminates this protection.","method":"Caspase-3/8/9 cleavage assays; PARP cleavage; annexin V staining; siRNA knockdown of PAR2, BAD, MCL-1; MEK and PI3K inhibitors; phospho-BAD immunoblotting","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — siRNA knockdown plus pharmacological dissection of two convergent pathways with multiple apoptosis readouts","pmids":["25331954"],"is_preprint":false},{"year":2014,"finding":"PAR2-induced TRPV4 channel activation is dependent on tyrosine kinases and PI3K but not Gαq or store-operated calcium entry (thapsigargin-insensitive); the tyrosine kinase inhibitor bafetinib, but not dasatinib, blocks PAR2-induced TRPV4 gating and mechanical hyperalgesia in vivo.","method":"Calcium imaging in HEK293 cells; TRPV4 transfection; pharmacological inhibitors; in vivo mechanical hyperalgesia assay","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2-3 — heterologous expression plus in vivo pharmacological validation; single lab","pmids":["24779362"],"is_preprint":false},{"year":2018,"finding":"PAR2 activation promotes M1-like macrophage polarization and proinflammatory cytokine expression through a FOXO1-dependent pathway; FOXO1 nuclear accumulation is required for PAR2-induced transcription of IL-1β, IL-6, MCP-1, and TNF-α, and FOXO1 siRNA knockdown abolishes this effect.","method":"Bone marrow-derived macrophages; PAR2 agonist stimulation; transcription factor microarray; qRT-PCR; western blot; immunofluorescence for FOXO1 localization; siRNA knockdown of FOXO1","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple methods but single lab; siRNA rescue validates pathway","pmids":["30552714"],"is_preprint":false},{"year":2018,"finding":"Plasma kallikrein modulates blood-brain barrier integrity via PAR2 on endothelial cells, leading to upregulation of ICAM-1 and VCAM-1 and amplified leukocyte trafficking; prekallikrein deficiency or blockade reduces BBB disruption and CNS inflammation in experimental autoimmune encephalomyelitis.","method":"In vitro endothelial cell PAR2 activation; ICAM-1/VCAM-1 upregulation assays; prekallikrein-deficient mice; EAE model; leukocyte trafficking quantification","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2-3 — in vitro mechanistic assay plus genetic model in vivo; single lab","pmids":["30559188"],"is_preprint":false},{"year":2013,"finding":"Kallikrein 6 (Klk6) signals through both PAR1 and PAR2 to activate ERK1/2 in neurons via phosphoinositide 3-kinase and MEK-dependent pathways, exacerbating glutamate neurotoxicity; lipopeptide inhibitors of PAR1 or PAR2, and PAR1 genetic deletion, each reduce Klk6-ERK1/2 activation.","method":"Recombinant Klk6 treatment of cerebellar granule neurons and NSC34 cells; PAR1/PAR2 lipopeptide inhibitors; PAR1 knockout mice; ERK1/2 activation assays; LDH/caspase assays","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological and genetic epistasis with multiple neuronal readouts; single lab","pmids":["23647384"],"is_preprint":false},{"year":2020,"finding":"PAR2 activation by tissue factor releases PTEN from its MAGI1-3 protein complex (demonstrated by proximity ligation assay and co-IP), transiently increasing PTEN lipid phosphatase activity and reducing Akt activity; prolonged TF exposure reduces PTEN antigen levels with concurrent Akt activation and increased proliferation.","method":"Proximity ligation assay; co-immunoprecipitation; PTEN/Akt phosphorylation assays; PAR2-agonist peptide; recombinant TF treatment; seven cancer cell lines","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — PLA and co-IP with functional kinase activity assays; single lab, multiple cell lines","pmids":["33262514"],"is_preprint":false},{"year":2018,"finding":"Mast cell tryptase promotes profibrotic phenotype in atrial fibroblasts via PAR2 and PPARγ pathways; the PAR2 antagonist FSLLRY-NH2 or PPARγ antagonist GW9662 abolishes tryptase-induced collagen I, fibronectin, laminin accumulation, and MMP upregulation.","method":"Primary atrial fibroblast culture; tryptase treatment; PAR2 antagonist; PPARγ antagonist; collagen/fibronectin/MMP western blots; cell proliferation and migration assays","journal":"Archives of medical research","confidence":"Medium","confidence_rationale":"Tier 3 — pharmacological antagonism with fibrotic readouts; single lab","pmids":["30580879"],"is_preprint":false},{"year":2022,"finding":"PAR2 activation in renal tubular epithelial cells induces chemokine (MCP1, MCP3) upregulation via the MAPK-NF-κB signaling pathway, driving inflammatory cell recruitment; PAR2-knockout mice are protected from adenine diet-induced renal fibrosis and inflammation.","method":"PAR2-knockout mice; adenine diet model; NRK52E epithelial cells; PAR2 agonist; MAPK and NF-κB inhibitors; qRT-PCR for chemokines; macrophage migration assay","journal":"Archives of pharmacal research","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic KO with in vitro pathway dissection; single lab","pmids":["35334088"],"is_preprint":false},{"year":2018,"finding":"PAR2 deficiency in MDSCs directly enhances their immunosuppressive activity through STAT3-mediated reactive oxygen species production, reshaping the tumor microenvironment to promote colorectal tumorigenesis.","method":"PAR2-KO mice; AOM/DSS colitis-associated cancer model; flow cytometry for MDSC/macrophage/T-cell infiltration; STAT3 pathway analysis; ROS measurement","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic KO with defined cellular phenotype and pathway identification; single lab","pmids":["31733286"],"is_preprint":false},{"year":2016,"finding":"PAR2 pepducin PZ-235, designed to mimic the juxtamembrane helical region of TM6/third intracellular loop, forms a well-structured α-helix and blocks PAR2-mediated reactive oxygen species production in hepatocytes and stellate cell activation, suppressing liver fibrosis, collagen deposition, and inflammation.","method":"NMR structure of PZ-235 peptide; mouse CCl4 and MCD diet fibrosis models; pepducin treatment; stellate cell activation assays; ROS assay; histology; collagen quantification","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 — NMR structural characterization of pepducin plus in vivo therapeutic validation","pmids":["27613872"],"is_preprint":false},{"year":2018,"finding":"PAR2 activation causes migraine-like pain behaviors (facial grimace and mechanical allodynia) upon dural application in mice; functional PAR2 is expressed on trigeminal neurons and dural fibroblasts; the effect is attenuated by PAR2 antagonist C391 and is absent in PAR2-/- mice.","method":"Ca2+ imaging of trigeminal neurons and dural fibroblasts; behavioral assays (grimace scale, von Frey); PAR2-KO mice; PAR2 antagonist C391; sumatriptan comparison","journal":"Cephalalgia : an international journal of headache","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO plus pharmacological antagonism with defined behavioral phenotype","pmids":["29848111"],"is_preprint":false},{"year":2018,"finding":"In differentiated human keratinocytes, PAR2-evoked Ca2+ store depletion and downstream inflammatory mediator production (IL-1β, TNF-α, TSLP) require both InsP3R and TRPV1 in intracellular Ca2+ stores, rather than ORAI1-mediated store-operated Ca2+ entry; PLC inhibition abolishes these responses.","method":"Ca2+ imaging; TRPV1/InsP3R/ORAI1 inhibitors; NF-κB activity assay; cytokine ELISA; PAR2-activating peptide SLIGKV in primary keratinocytes","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological dissection with multiple readouts in primary human cells; single lab","pmids":["29458120"],"is_preprint":false},{"year":2013,"finding":"MicroRNA-34a mediates PAR2-induced upregulation of Cyclin D1 in colon cancer cells; TGF-β contributes to PAR2 regulation of miR-34a; PAR2 knockdown or inactivation of its autocrine activating proteinase reduces proliferation in vitro and tumorigenicity in vivo.","method":"siRNA knockdown of PAR2; miR-34a inhibitor; Cyclin D1 expression; in vitro proliferation; xenograft mouse model; TGF-β pathway analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 — siRNA plus in vivo xenograft model with miRNA mechanistic link","pmids":["23991105"],"is_preprint":false}],"current_model":"PAR2 (F2RL1) is a G protein-coupled receptor activated by serine proteases (trypsin, tryptase, coagulation factors VIIa/Xa) and cysteine proteases (cathepsin S) that cleave its N-terminus to unmask a tethered ligand; it signals through multiple G proteins (Gαq, Gα12/13, Gαi, Gαs) and β-arrestins to regulate TRPA1/TRPV4 sensitization (via PLC-PIP2), ERK1/2 activation, NF-κB, RhoA/Rho kinase, PI3K/Akt, and cAMP/PKA pathways; it forms heterodimers with PAR1, PAR3, and PAR4 that alter trafficking and signaling; endocytosis-dependent endosomal signaling complexes sustain inflammatory and nociceptive responses; and PAR2 plays defined roles in neurogenic inflammation and pain, skin barrier homeostasis, liver glucose and lipid metabolism, pulmonary and hepatic fibrosis, and immune regulation."},"narrative":{"teleology":[{"year":2002,"claim":"Identifying TF/FVIIa as a PAR2 ligand in vascular cells established that coagulation proteases drive PAR2-dependent cell migration, linking hemostasis to vascular remodeling.","evidence":"Boyden chamber migration assay with PAR2-activating peptide and neutralizing antisera in smooth muscle cells","pmids":["12479889"],"confidence":"Medium","gaps":["Downstream signaling pathway not dissected","Single cell type tested","No genetic confirmation"]},{"year":2007,"claim":"Demonstrating that PAR2 sensitizes TRPA1 through PLC-mediated PIP2 hydrolysis resolved how protease signaling couples to nociceptive ion channels and provided a molecular mechanism for inflammatory pain.","evidence":"Electrophysiology in HEK293 cells and DRG neurons with PLC inhibitors and PIP2 antibody sequestration","pmids":["17571167"],"confidence":"High","gaps":["In vivo behavioral validation of PIP2 mechanism not shown in this study","Whether TRPV1 is co-regulated by the same mechanism unclear"]},{"year":2008,"claim":"Identification of two independent, non-overlapping PAR2 signaling branches—MEK/ERK and PI3K/Akt—converging on IL-8 release revealed how PAR2 achieves robust inflammatory cytokine output through pathway redundancy.","evidence":"Pharmacological inhibition of MEK and PI3K with phospho-protein and cytokine readouts in GI epithelial cells","pmids":["18854173"],"confidence":"Medium","gaps":["No genetic knockdown confirmation","G protein coupling to each branch not identified"]},{"year":2011,"claim":"Genetic epistasis showing that the skin pathology of CAP1/Prss8 overexpression is completely abolished on a PAR2-null background established PAR2 as the obligate downstream effector of this protease in epidermal homeostasis.","evidence":"Transgenic K14-CAP1/Prss8 mice crossed to PAR2-null background; histology, barrier function, and cytokine assays","pmids":["21245842"],"confidence":"High","gaps":["Direct cleavage of PAR2 by CAP1/Prss8 not biochemically demonstrated","Downstream PAR2 signaling pathway in keratinocytes not identified"]},{"year":2012,"claim":"Discovery that PAR2 promotes PAR4 plasma membrane delivery by disrupting β-COP1-mediated ER retention and recruiting 14-3-3ζ revealed PAR2's role as a chaperone for other PARs, expanding the concept of GPCR heterodimerization beyond co-signaling to trafficking control.","evidence":"FRET, co-immunoprecipitation, mutagenesis of PAR4 RXR ER-retention motif, glycosylation and signaling assays","pmids":["22411985"],"confidence":"High","gaps":["Whether PAR2 similarly chaperones PAR3 unknown","Structural basis of PAR2-PAR4 interface not resolved"]},{"year":2013,"claim":"Characterization of PAR1–PAR2 heterodimer constitutive internalization and endosomal β-arrestin–ERK signaling, together with the finding that PAR2 couples to Gq/G13/Gi with RhoA feedback inhibition via NF-κB–PKA in smooth muscle, defined how heterodimerization and G protein multiplicity shape PAR2 signaling output.","evidence":"BRET, co-IP, and ERK assays for PAR1–PAR2 heterodimers; siRNA/minigene/pertussis toxin dissection in gastric smooth muscle","pmids":["23476015","23825105"],"confidence":"High","gaps":["Structural determinants of PAR1–PAR2 heterodimerization interface not defined","Whether RhoA–PKA feedback operates outside smooth muscle untested"]},{"year":2014,"claim":"Identification of cathepsin S as a biased agonist cleaving PAR2 at a non-canonical site (Glu56↓Thr57) to selectively engage Gαs/cAMP without β-arrestin or Ca²⁺ mobilization fundamentally changed the model of PAR2 activation from a single tethered-ligand mechanism to protease-specific biased agonism.","evidence":"Cleavage-site mapping, cAMP/Ca²⁺/β-arrestin assays, TRPV4 functional assay in oocytes, PAR2/TRPV4 KO mice","pmids":["25118282","24964046"],"confidence":"High","gaps":["Whether other cysteine proteases produce similar bias unknown","Structural basis for bias at receptor level not resolved"]},{"year":2014,"claim":"Demonstration that PAR2 protects epithelial cells from cytokine-induced apoptosis through convergent MEK–BAD(Ser112) and PI3K–BAD(Ser136) phosphorylation established a cytoprotective function for PAR2 and explained why both pathways must be inhibited simultaneously to block survival signaling.","evidence":"Caspase/PARP cleavage, annexin V, phospho-BAD immunoblotting, PAR2 siRNA, MEK/PI3K inhibitors","pmids":["25331954"],"confidence":"High","gaps":["Upstream G protein coupling to each survival branch not identified","In vivo relevance of anti-apoptotic function not tested"]},{"year":2015,"claim":"Two studies established PAR2 as a critical mediator in fibrosis and innate immunity: PAR2 was shown to be required for PAR1-dependent pulmonary fibrosis, and EPCR-dependent PAR2 activation by the TF–VIIa–Xa complex was found to initiate an interferon gene program via Pellino-1/IRF8.","evidence":"PAR2-KO mice in bleomycin fibrosis model; PAR2/EPCR-KO mice with LPS challenge and mRNA profiling","pmids":["25689283","25733582"],"confidence":"High","gaps":["Whether PAR1–PAR2 heterodimerization is the mechanism underlying PAR2 requirement in fibrosis not directly tested","How EPCR scaffolding alters PAR2 cleavage specificity unknown"]},{"year":2017,"claim":"Discovery that activated protein C signals through PAR2/PAR3 heterodimers on Tregs to restrain alloreactive T cells and ameliorate graft-versus-host disease linked PAR2 to adaptive immune regulation and established a non-inflammatory, immunosuppressive role for PAR2.","evidence":"PAR2/PAR3-KO mice; allogeneic HSCT model; humanized NSG mouse model; Treg frequency analysis","pmids":["28827518"],"confidence":"High","gaps":["Downstream signaling pathway in Tregs not dissected","Whether aPC-PAR2/PAR3 axis operates in solid organ transplant tolerance unknown"]},{"year":2018,"claim":"Multiple studies in 2018 expanded PAR2's tissue-specific roles: plasma kallikrein activates PAR2 to disrupt the blood-brain barrier via ICAM-1/VCAM-1; PAR2 drives FOXO1-dependent M1 macrophage polarization; mast cell tryptase signals through PAR2–PPARγ to promote atrial fibrosis; and PAR2 on trigeminal neurons mediates migraine-like pain.","evidence":"Endothelial PAR2 activation with prekallikrein-KO EAE model; macrophage FOXO1 siRNA; atrial fibroblast PAR2/PPARγ antagonism; dural PAR2-KO mice with behavioral pain assays","pmids":["30559188","30552714","30580879","29848111"],"confidence":"Medium","gaps":["Integration of these tissue-specific findings into a unified signaling framework lacking","Whether migraine mechanism involves endosomal PAR2 signaling unknown","PPARγ link to canonical PAR2 G protein pathways not established"]},{"year":2019,"claim":"Identification of furin as the principal proprotein convertase processing PAR2 at Arg36, modulated by N-glycosylation at Asn30, revealed a post-translational regulatory layer controlling PAR2 activation efficiency and selectivity, with functional consequences in HIV-1-associated neurotoxicity.","evidence":"In vitro cleavage assays with site-directed mutagenesis; neuroblastoma-macrophage co-culture with HIV-1","pmids":["30683917"],"confidence":"High","gaps":["Whether furin activates PAR2 in trans at the cell surface or in the secretory pathway not distinguished","Relevance of this processing to other PAR2 disease contexts untested"]},{"year":2019,"claim":"Demonstration that PAR2-KO mice have ~50% reduced plasma and hepatic cholesterol via decreased synthesis genes and increased reverse cholesterol transport, mediated by Gi–JNK1/2 signaling, established PAR2 as a metabolic regulator of cholesterol homeostasis.","evidence":"PAR2-KO mice on normal and high-fat diets; plasma/liver lipid profiling; fecal bile acid output; pathway inhibitors","pmids":["31668396"],"confidence":"High","gaps":["Whether hepatocyte-specific or systemic PAR2 deletion is responsible not resolved","Identity of the endogenous activating protease in metabolic context unknown"]},{"year":2020,"claim":"CRISPR-based dissection of PAR2 signaling in ovarian cancer revealed that migration/invasion absolutely requires cooperative Gαq/11, Gα12/13, and β-arrestin1/2 engagement driving Src–EGFR transactivation–MEK–ERK–transcription factor cascades, while a negative allosteric modulator selectively blocking Gαq/Gα12/13 was sufficient to suppress inflammation in vivo.","evidence":"CRISPR-KO of individual G proteins and β-arrestins in cancer cells; BRET signaling profiling of PAR2 inhibitor I-287; in vivo inflammation model","pmids":["33226635","33247181"],"confidence":"High","gaps":["Whether pathway cooperativity requirement is cancer-type specific untested","Structural basis for allosteric modulator selectivity not resolved"]},{"year":2022,"claim":"Three 2022 studies completed the picture of PAR2 compartmentalized signaling and metabolic function: endosomal PAR2 assemblies (Gαq/Gαi/β-arrestin) in colonocytes sustain colitis; GPR97 allosterically activates mPR3 within a CD177/GPR97/PAR2/CD16b neutrophil complex; and liver-specific PAR2-KO rescues glucose/glycogen defects by restoring GLUT2 and insulin-Akt signaling.","evidence":"PAR2-muGFP knockin mice with dynamin inhibition in colitis; GPR97 crystal structure with co-IP and neutrophil activation; liver-specific PAR2-KO with pepducin treatment and metabolic phenotyping","pmids":["35110404","36302784","35603482"],"confidence":"High","gaps":["How endosomal vs. surface PAR2 signals are decoded differently at the transcriptional level unknown","Whether CD177/GPR97/PAR2 complex exists outside neutrophils not tested","Identity of endogenous hepatic PAR2 activating protease still unresolved"]},{"year":null,"claim":"Major unresolved questions include the identity of endogenous PAR2-activating proteases in hepatic metabolic regulation, the structural basis for protease-specific biased agonism at the receptor level, how endosomal versus surface PAR2 signals are differentially decoded, and whether PAR2 heterodimer combinations produce distinct functional outcomes across additional tissue contexts.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution PAR2 structure in complex with tethered ligand variants","Endogenous protease activating hepatic PAR2 unknown","Systematic comparison of heterodimer signaling profiles lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,5,6,11,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,9,13]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4,6,10,11]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[3,6]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,5,6,11,14,15,16]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,9,22,23,28]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[7,18]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[0,1,30]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[15,16]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[20]}],"complexes":["PAR1-PAR2 heterodimer","PAR2-PAR3 heterodimer","PAR2-PAR4 heterodimer","CD177/GPR97/PAR2/CD16b complex"],"partners":["F2R","F2RL2","F2RL3","TRPA1","TRPV4","PROCR","ADGRF5","TGFBR1"],"other_free_text":[]},"mechanistic_narrative":"F2RL1 (PAR2) is a protease-activated G protein-coupled receptor that transduces extracellular proteolytic signals into diverse intracellular cascades governing inflammation, pain, tissue remodeling, and metabolic homeostasis. Serine proteases (trypsin, tryptase, coagulation factors VIIa/Xa, kallikrein 6, proteinase 3, CAP1/Prss8) and the cysteine protease cathepsin S cleave the PAR2 N-terminus at distinct sites to unmask different tethered ligands, producing biased signaling: canonical cleavage at Arg36 activates Gαq/Gα12/13/Gαi and β-arrestin pathways driving PLC–PIP2 hydrolysis, RhoA/Rho kinase, MEK–ERK1/2, PI3K–Akt, and NF-κB, whereas cathepsin S cleavage at Glu56 selectively engages Gαs/cAMP/PKA to sensitize TRPV4 channels [PMID:17571167, PMID:25118282, PMID:23825105, PMID:33226635]. PAR2 forms functional heterodimers with PAR1, PAR3, and PAR4 that alter receptor trafficking, β-arrestin–mediated endosomal ERK signaling, and immune regulation—including activated protein C–driven Treg expansion via PAR2/PAR3 heterodimers—and dynamin-2-dependent endocytosis sustains PAR2 endosomal signaling complexes required for colonic inflammation and hyperalgesia [PMID:23476015, PMID:22411985, PMID:28827518, PMID:35110404]. In metabolic tissues, hepatic PAR2 suppresses glucose uptake through Gq–MAPK–FoxA3-dependent GLUT2 downregulation and Gq–CaMKK2-mediated inhibition of insulin–Akt signaling, while PAR2–Gi–JNK1/2 signaling regulates cholesterol synthesis and reverse cholesterol transport [PMID:35603482, PMID:31668396]."},"prefetch_data":{"uniprot":{"accession":"P55085","full_name":"Proteinase-activated receptor 2","aliases":["Coagulation factor II receptor-like 1","G-protein coupled receptor 11","Thrombin receptor-like 1"],"length_aa":397,"mass_kda":44.1,"function":"Receptor for trypsin and trypsin-like enzymes coupled to G proteins (PubMed:28445455). Its function is mediated through the activation of several signaling pathways including phospholipase C (PLC), intracellular calcium, mitogen-activated protein kinase (MAPK), I-kappaB kinase/NF-kappaB and Rho (PubMed:28445455). Can also be transactivated by cleaved F2R/PAR1. Involved in modulation of inflammatory responses and regulation of innate and adaptive immunity, and acts as a sensor for proteolytic enzymes generated during infection. Generally is promoting inflammation. Can signal synergistically with TLR4 and probably TLR2 in inflammatory responses and modulates TLR3 signaling. Has a protective role in establishing the endothelial barrier; the activity involves coagulation factor X. Regulates endothelial cell barrier integrity during neutrophil extravasation, probably following proteolytic cleavage by PRTN3 (PubMed:23202369). Proposed to have a bronchoprotective role in airway epithelium, but also shown to compromise the airway epithelial barrier by interrupting E-cadherin adhesion (PubMed:10086357). Involved in the regulation of vascular tone; activation results in hypotension presumably mediated by vasodilation. Associates with a subset of G proteins alpha subunits such as GNAQ, GNA11, GNA14, GNA12 and GNA13, but probably not with G(o)-alpha, G(i) subunit alpha-1 and G(i) subunit alpha-2. However, according to PubMed:21627585 can signal through G(i) subunit alpha. Believed to be a class B receptor which internalizes as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptor, for extended periods of time. Mediates inhibition of TNF stimulated JNK phosphorylation via coupling to GNAQ and GNA11; the function involves dissociation of RIPK1 and TRADD from TNFR1. Mediates phosphorylation of nuclear factor NF-kappa-B RELA subunit at 'Ser-536'; the function involves IKBKB and is predominantly independent of G proteins. Involved in cellular migration. Involved in cytoskeletal rearrangement and chemotaxis through beta-arrestin-promoted scaffolds; the function is independent of GNAQ and GNA11 and involves promotion of cofilin dephosphorylation and actin filament severing. Induces redistribution of COPS5 from the plasma membrane to the cytosol and activation of the JNK cascade is mediated by COPS5. Involved in the recruitment of leukocytes to the sites of inflammation and is the major PAR receptor capable of modulating eosinophil function such as pro-inflammatory cytokine secretion, superoxide production and degranulation. During inflammation promotes dendritic cell maturation, trafficking to the lymph nodes and subsequent T-cell activation. Involved in antimicrobial response of innate immune cells; activation enhances phagocytosis of Gram-positive and killing of Gram-negative bacteria. Acts synergistically with interferon-gamma in enhancing antiviral responses. Implicated in a number of acute and chronic inflammatory diseases such as of the joints, lungs, brain, gastrointestinal tract, periodontium, skin, and vascular systems, and in autoimmune disorders. Probably mediates activation of pro-inflammatory and pro-fibrotic responses in fibroblasts, triggered by coagulation factor Xa (F10) (By similarity). Mediates activation of barrier protective signaling responses in endothelial cells, triggered by coagulation factor Xa (F10) (PubMed:22409427)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P55085/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/F2RL1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/F2RL1","total_profiled":1310},"omim":[{"mim_id":"610499","title":"RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR 6; RAPGEF6","url":"https://www.omim.org/entry/610499"},{"mim_id":"607092","title":"SPHINGOSINE KINASE 2; SPHK2","url":"https://www.omim.org/entry/607092"},{"mim_id":"607003","title":"THYMIC STROMAL LYMPHOPOIETIN; TSLP","url":"https://www.omim.org/entry/607003"},{"mim_id":"603730","title":"SPHINGOSINE KINASE 1; SPHK1","url":"https://www.omim.org/entry/603730"},{"mim_id":"601974","title":"SPHINGOSINE-1-PHOSPHATE RECEPTOR 1; S1PR1","url":"https://www.omim.org/entry/601974"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":55.6},{"tissue":"stomach 1","ntpm":41.6}],"url":"https://www.proteinatlas.org/search/F2RL1"},"hgnc":{"alias_symbol":["PAR2"],"prev_symbol":["GPR11"]},"alphafold":{"accession":"P55085","domains":[{"cath_id":"1.20.1070.10","chopping":"57-354","consensus_level":"medium","plddt":91.098,"start":57,"end":354}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P55085","model_url":"https://alphafold.ebi.ac.uk/files/AF-P55085-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P55085-F1-predicted_aligned_error_v6.png","plddt_mean":82.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=F2RL1","jax_strain_url":"https://www.jax.org/strain/search?query=F2RL1"},"sequence":{"accession":"P55085","fasta_url":"https://rest.uniprot.org/uniprotkb/P55085.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P55085/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P55085"}},"corpus_meta":[{"pmid":"17571167","id":"PMC_17571167","title":"Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17571167","citation_count":355,"is_preprint":false},{"pmid":"25118282","id":"PMC_25118282","title":"Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25118282","citation_count":158,"is_preprint":false},{"pmid":"19661489","id":"PMC_19661489","title":"Tissue factor and PAR2 signaling in the tumor microenvironment.","date":"2009","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19661489","citation_count":98,"is_preprint":false},{"pmid":"11448145","id":"PMC_11448145","title":"Protease-activated receptor-2 (PAR2) in the airways.","date":"2001","source":"Pulmonary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/11448145","citation_count":98,"is_preprint":false},{"pmid":"21245842","id":"PMC_21245842","title":"PAR2 absence completely rescues inflammation and ichthyosis caused by altered CAP1/Prss8 expression in mouse skin.","date":"2011","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/21245842","citation_count":95,"is_preprint":false},{"pmid":"21296894","id":"PMC_21296894","title":"Alternaria alternata serine proteases induce lung inflammation and airway epithelial cell activation via PAR2.","date":"2011","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21296894","citation_count":92,"is_preprint":false},{"pmid":"23476015","id":"PMC_23476015","title":"Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits β-arrestin-mediated endosomal signaling.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23476015","citation_count":79,"is_preprint":false},{"pmid":"25733582","id":"PMC_25733582","title":"EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25733582","citation_count":72,"is_preprint":false},{"pmid":"23895492","id":"PMC_23895492","title":"Toward drugs for protease-activated receptor 2 (PAR2).","date":"2013","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23895492","citation_count":70,"is_preprint":false},{"pmid":"23055487","id":"PMC_23055487","title":"Novel animal models of acute and chronic cancer pain: a pivotal role for PAR2.","date":"2012","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23055487","citation_count":69,"is_preprint":false},{"pmid":"11828045","id":"PMC_11828045","title":"Expression of protease activated receptor-2 (PAR-2) in central airways of smokers and non-smokers.","date":"2002","source":"Thorax","url":"https://pubmed.ncbi.nlm.nih.gov/11828045","citation_count":64,"is_preprint":false},{"pmid":"12479889","id":"PMC_12479889","title":"Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex.","date":"2002","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/12479889","citation_count":60,"is_preprint":false},{"pmid":"30552714","id":"PMC_30552714","title":"PAR2 promotes M1 macrophage polarization and inflammation via FOXO1 pathway.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30552714","citation_count":59,"is_preprint":false},{"pmid":"19889021","id":"PMC_19889021","title":"Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation.","date":"2009","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19889021","citation_count":55,"is_preprint":false},{"pmid":"24335334","id":"PMC_24335334","title":"Both PHYTOCHROME RAPIDLY REGULATED1 (PAR1) and PAR2 promote seedling photomorphogenesis in multiple light signaling pathways.","date":"2013","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24335334","citation_count":55,"is_preprint":false},{"pmid":"33072072","id":"PMC_33072072","title":"Macrophage TLR4 and PAR2 Signaling: Role in Regulating Vascular Inflammatory Injury and Repair.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33072072","citation_count":54,"is_preprint":false},{"pmid":"30287285","id":"PMC_30287285","title":"PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30287285","citation_count":53,"is_preprint":false},{"pmid":"23647384","id":"PMC_23647384","title":"Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity.","date":"2013","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23647384","citation_count":53,"is_preprint":false},{"pmid":"27613872","id":"PMC_27613872","title":"Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27613872","citation_count":51,"is_preprint":false},{"pmid":"24964046","id":"PMC_24964046","title":"Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24964046","citation_count":50,"is_preprint":false},{"pmid":"16869943","id":"PMC_16869943","title":"Induction of IL-6 release from human T cells by PAR-1 and PAR-2 agonists.","date":"2006","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16869943","citation_count":49,"is_preprint":false},{"pmid":"25331954","id":"PMC_25331954","title":"Proteinase-activated receptor 2 (PAR2) decreases apoptosis in colonic epithelial cells.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25331954","citation_count":49,"is_preprint":false},{"pmid":"18854173","id":"PMC_18854173","title":"PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18854173","citation_count":49,"is_preprint":false},{"pmid":"26312432","id":"PMC_26312432","title":"Functional inhibition of PAR2 alleviates allergen-induced airway hyperresponsiveness and inflammation.","date":"2015","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26312432","citation_count":48,"is_preprint":false},{"pmid":"29795022","id":"PMC_29795022","title":"Signaling Crosstalk of TGF-β/ALK5 and PAR2/PAR1: A Complex Regulatory Network Controlling Fibrosis and Cancer.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29795022","citation_count":47,"is_preprint":false},{"pmid":"24779362","id":"PMC_24779362","title":"The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo.","date":"2014","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24779362","citation_count":47,"is_preprint":false},{"pmid":"29599135","id":"PMC_29599135","title":"PAR2 (Protease-Activated Receptor 2) Deficiency Attenuates Atherosclerosis in Mice.","date":"2018","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29599135","citation_count":45,"is_preprint":false},{"pmid":"31841119","id":"PMC_31841119","title":"Protease-activated receptor 2 (PAR-2) antagonist AZ3451 as a novel therapeutic agent for osteoarthritis.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31841119","citation_count":45,"is_preprint":false},{"pmid":"30559188","id":"PMC_30559188","title":"Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30559188","citation_count":44,"is_preprint":false},{"pmid":"29848111","id":"PMC_29848111","title":"Protease activated receptor 2 (PAR2) activation causes migraine-like pain behaviors in mice.","date":"2018","source":"Cephalalgia : an international journal of headache","url":"https://pubmed.ncbi.nlm.nih.gov/29848111","citation_count":42,"is_preprint":false},{"pmid":"23991105","id":"PMC_23991105","title":"MicroRNA-34a mediates the autocrine signaling of PAR2-activating proteinase and its role in colonic cancer cell proliferation.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23991105","citation_count":42,"is_preprint":false},{"pmid":"15668333","id":"PMC_15668333","title":"Proteinase-activated receptor-2 (PAR2) agonist causes periodontitis in rats.","date":"2005","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/15668333","citation_count":41,"is_preprint":false},{"pmid":"35603482","id":"PMC_35603482","title":"PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference.","date":"2022","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/35603482","citation_count":40,"is_preprint":false},{"pmid":"24907413","id":"PMC_24907413","title":"Role for β-arrestin in mediating paradoxical β2AR and PAR2 signaling in asthma.","date":"2014","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24907413","citation_count":40,"is_preprint":false},{"pmid":"22411985","id":"PMC_22411985","title":"Novel role for proteinase-activated receptor 2 (PAR2) in membrane trafficking of proteinase-activated receptor 4 (PAR4).","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22411985","citation_count":40,"is_preprint":false},{"pmid":"23825105","id":"PMC_23825105","title":"Distinctive G Protein-Dependent Signaling by Protease-Activated Receptor 2 (PAR2) in Smooth Muscle: Feedback Inhibition of RhoA by cAMP-Independent PKA.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23825105","citation_count":39,"is_preprint":false},{"pmid":"28827518","id":"PMC_28827518","title":"Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28827518","citation_count":38,"is_preprint":false},{"pmid":"35110404","id":"PMC_35110404","title":"Mice expressing fluorescent PAR2 reveal that endocytosis mediates colonic inflammation and pain.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35110404","citation_count":37,"is_preprint":false},{"pmid":"16425301","id":"PMC_16425301","title":"Expression of protease activated receptor-2 (PAR-2) in gastric cancer.","date":"2006","source":"Journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16425301","citation_count":37,"is_preprint":false},{"pmid":"14585156","id":"PMC_14585156","title":"PAR-2: structure, function and relevance to human diseases of the gastric mucosa.","date":"2002","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14585156","citation_count":36,"is_preprint":false},{"pmid":"15482468","id":"PMC_15482468","title":"Protease-activated receptor-2 (PAR-2) expression in human fibroblasts is regulated by growth factors and extracellular matrix.","date":"2004","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15482468","citation_count":35,"is_preprint":false},{"pmid":"33226635","id":"PMC_33226635","title":"PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR.","date":"2020","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33226635","citation_count":34,"is_preprint":false},{"pmid":"29458120","id":"PMC_29458120","title":"Major Role for TRPV1 and InsP3R in PAR2-Elicited Inflammatory Mediator Production in Differentiated Human Keratinocytes.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/29458120","citation_count":34,"is_preprint":false},{"pmid":"38228638","id":"PMC_38228638","title":"Enhancing aortic valve drug delivery with PAR2-targeting magnetic nano-cargoes for calcification alleviation.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38228638","citation_count":33,"is_preprint":false},{"pmid":"20530726","id":"PMC_20530726","title":"Protease-activated receptor-2 (PAR(2)) in human periodontitis.","date":"2010","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/20530726","citation_count":33,"is_preprint":false},{"pmid":"12139406","id":"PMC_12139406","title":"Ion transport induced by proteinase-activated receptors (PAR2) in colon and airways.","date":"2002","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/12139406","citation_count":32,"is_preprint":false},{"pmid":"26140338","id":"PMC_26140338","title":"The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivo.","date":"2015","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26140338","citation_count":32,"is_preprint":false},{"pmid":"31733286","id":"PMC_31733286","title":"PAR2 deficiency enhances myeloid cell-mediated immunosuppression and promotes colitis-associated tumorigenesis.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/31733286","citation_count":31,"is_preprint":false},{"pmid":"30560330","id":"PMC_30560330","title":"Mechanisms of Probiotic VSL#3 in a Rat Model of Visceral Hypersensitivity Involves the Mast Cell-PAR2-TRPV1 Pathway.","date":"2018","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30560330","citation_count":31,"is_preprint":false},{"pmid":"30841957","id":"PMC_30841957","title":"PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling.","date":"2019","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/30841957","citation_count":29,"is_preprint":false},{"pmid":"36302784","id":"PMC_36302784","title":"GPR97 triggers inflammatory processes in human neutrophils via a macromolecular complex upstream of PAR2 activation.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36302784","citation_count":28,"is_preprint":false},{"pmid":"33247181","id":"PMC_33247181","title":"The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/33247181","citation_count":28,"is_preprint":false},{"pmid":"25689283","id":"PMC_25689283","title":"Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25689283","citation_count":27,"is_preprint":false},{"pmid":"22914544","id":"PMC_22914544","title":"Variants in CXADR and F2RL1 are associated with blood pressure and obesity in African-Americans in regions identified through admixture mapping.","date":"2012","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/22914544","citation_count":26,"is_preprint":false},{"pmid":"29261154","id":"PMC_29261154","title":"The Role of PAR2 in TGF-β1-Induced ERK Activation and Cell Motility.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29261154","citation_count":26,"is_preprint":false},{"pmid":"35334088","id":"PMC_35334088","title":"Renal tubular PAR2 promotes interstitial fibrosis by increasing inflammatory responses and EMT process.","date":"2022","source":"Archives of pharmacal research","url":"https://pubmed.ncbi.nlm.nih.gov/35334088","citation_count":26,"is_preprint":false},{"pmid":"31668396","id":"PMC_31668396","title":"PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease.","date":"2019","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31668396","citation_count":26,"is_preprint":false},{"pmid":"16195539","id":"PMC_16195539","title":"RNA interference decreases PAR-2 expression and function in human airway smooth muscle cells.","date":"2005","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16195539","citation_count":26,"is_preprint":false},{"pmid":"21029417","id":"PMC_21029417","title":"PAR1- and PAR2-induced innate immune markers are negatively regulated by PI3K/Akt signaling pathway in oral keratinocytes.","date":"2010","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21029417","citation_count":26,"is_preprint":false},{"pmid":"22294633","id":"PMC_22294633","title":"PAR(2) expression in peripheral blood monocytes of patients with rheumatoid arthritis.","date":"2012","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22294633","citation_count":26,"is_preprint":false},{"pmid":"21294569","id":"PMC_21294569","title":"Potent agonists of the protease activated receptor 2 (PAR2).","date":"2011","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21294569","citation_count":25,"is_preprint":false},{"pmid":"32674502","id":"PMC_32674502","title":"Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32674502","citation_count":25,"is_preprint":false},{"pmid":"15320742","id":"PMC_15320742","title":"Proteinase-activated Receptor 2 (PAR2): a challenging new target for treatment of vascular diseases.","date":"2004","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/15320742","citation_count":25,"is_preprint":false},{"pmid":"33131305","id":"PMC_33131305","title":"Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine.","date":"2020","source":"Cephalalgia : an international journal of headache","url":"https://pubmed.ncbi.nlm.nih.gov/33131305","citation_count":25,"is_preprint":false},{"pmid":"19704482","id":"PMC_19704482","title":"PAR1 and PAR2 integrate shade and hormone transcriptional networks.","date":"2008","source":"Plant signaling & behavior","url":"https://pubmed.ncbi.nlm.nih.gov/19704482","citation_count":24,"is_preprint":false},{"pmid":"28245465","id":"PMC_28245465","title":"Astragaloside Alleviates Hepatic Fibrosis Function via PAR2 Signaling Pathway in Diabetic Rats.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28245465","citation_count":24,"is_preprint":false},{"pmid":"17936340","id":"PMC_17936340","title":"Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation.","date":"2007","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17936340","citation_count":24,"is_preprint":false},{"pmid":"16483565","id":"PMC_16483565","title":"The protease-activated receptor2 (PAR2)-prostaglandin E2-prostanoid EP receptor axis: a potential bronchoprotective unit in the respiratory tract?","date":"2006","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16483565","citation_count":24,"is_preprint":false},{"pmid":"26936077","id":"PMC_26936077","title":"Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).","date":"2016","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/26936077","citation_count":23,"is_preprint":false},{"pmid":"37131291","id":"PMC_37131291","title":"Crohn's disease proteolytic microbiota enhances inflammation through PAR2 pathway in gnotobiotic mice.","date":"2023","source":"Gut microbes","url":"https://pubmed.ncbi.nlm.nih.gov/37131291","citation_count":23,"is_preprint":false},{"pmid":"24876278","id":"PMC_24876278","title":"Protease-activated receptor 2 (PAR2) is upregulated by Acanthamoeba plasminogen activator (aPA) and induces proinflammatory cytokine in human corneal epithelial cells.","date":"2014","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/24876278","citation_count":22,"is_preprint":false},{"pmid":"30973971","id":"PMC_30973971","title":"Aspergillus fumigatus induction of IL-33 expression in chronic rhinosinusitis is PAR2-dependent.","date":"2019","source":"The Laryngoscope","url":"https://pubmed.ncbi.nlm.nih.gov/30973971","citation_count":21,"is_preprint":false},{"pmid":"31487753","id":"PMC_31487753","title":"House dust mite-treated PAR2 over-expressor mouse: A novel model of atopic dermatitis.","date":"2019","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/31487753","citation_count":21,"is_preprint":false},{"pmid":"27809303","id":"PMC_27809303","title":"PAR2 regulates regeneration, transdifferentiation, and death.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27809303","citation_count":20,"is_preprint":false},{"pmid":"19086162","id":"PMC_19086162","title":"Proteinase-activated receptor 2 (PAR-2) in gastrointestinal and pancreatic pathophysiology, inflammation and neoplasia.","date":"2008","source":"Scandinavian journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19086162","citation_count":20,"is_preprint":false},{"pmid":"27524610","id":"PMC_27524610","title":"Cortical Polarity of the RING Protein PAR-2 Is Maintained by Exchange Rate Kinetics at the Cortical-Cytoplasmic Boundary.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27524610","citation_count":20,"is_preprint":false},{"pmid":"35844627","id":"PMC_35844627","title":"Candida albicans Sap6 Initiates Oral Mucosal Inflammation via the Protease Activated Receptor PAR2.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35844627","citation_count":20,"is_preprint":false},{"pmid":"16183333","id":"PMC_16183333","title":"Protease-activated receptor-2 (PAR2) in cardiovascular system.","date":"2005","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16183333","citation_count":19,"is_preprint":false},{"pmid":"30580879","id":"PMC_30580879","title":"Tryptase Promotes the Profibrotic Phenotype Transfer of Atrial Fibroblasts by PAR2 and PPARγ Pathway.","date":"2018","source":"Archives of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/30580879","citation_count":19,"is_preprint":false},{"pmid":"17335921","id":"PMC_17335921","title":"Protease-activated receptor-1 (PAR1) and PAR2 but not PAR4 mediate relaxations in lower esophageal sphincter.","date":"2007","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/17335921","citation_count":19,"is_preprint":false},{"pmid":"37339634","id":"PMC_37339634","title":"Excess pancreatic elastase alters acinar-β cell communication by impairing the mechano-signaling and the PAR2 pathways.","date":"2023","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37339634","citation_count":17,"is_preprint":false},{"pmid":"30683917","id":"PMC_30683917","title":"HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/30683917","citation_count":17,"is_preprint":false},{"pmid":"35772632","id":"PMC_35772632","title":"Activation of PAR2 promotes high-fat diet-induced renal injury by inducing oxidative stress and inflammation.","date":"2022","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/35772632","citation_count":17,"is_preprint":false},{"pmid":"22731117","id":"PMC_22731117","title":"Transient early neurotrophin release and delayed inflammatory cytokine release by microglia in response to PAR-2 stimulation.","date":"2012","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/22731117","citation_count":16,"is_preprint":false},{"pmid":"39418848","id":"PMC_39418848","title":"PAR2 on oral cancer cells and nociceptors contributes to oral cancer pain that can be relieved by nanoparticle-encapsulated AZ3451.","date":"2024","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/39418848","citation_count":16,"is_preprint":false},{"pmid":"33602818","id":"PMC_33602818","title":"Genetic priming of sensory neurons in mice that overexpress PAR2 enhances allergen responsiveness.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33602818","citation_count":16,"is_preprint":false},{"pmid":"35663777","id":"PMC_35663777","title":"A re-innervated in vitro skin model of non-histaminergic itch and skin neurogenic inflammation: PAR2-, TRPV1- and TRPA1-agonist induced functionality.","date":"2021","source":"Skin health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/35663777","citation_count":16,"is_preprint":false},{"pmid":"38687090","id":"PMC_38687090","title":"PAR2-mediated cellular senescence promotes inflammation and fibrosis in aging and chronic kidney disease.","date":"2024","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/38687090","citation_count":15,"is_preprint":false},{"pmid":"38816842","id":"PMC_38816842","title":"Par2-mediated responses in inflammation and regeneration: choosing between repair and damage.","date":"2024","source":"Inflammation and regeneration","url":"https://pubmed.ncbi.nlm.nih.gov/38816842","citation_count":15,"is_preprint":false},{"pmid":"20651095","id":"PMC_20651095","title":"PAR(2) and temporomandibular joint inflammation in the rat.","date":"2010","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/20651095","citation_count":15,"is_preprint":false},{"pmid":"26089202","id":"PMC_26089202","title":"Regulation of SPRY3 by X chromosome and PAR2-linked promoters in an autism susceptibility region.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26089202","citation_count":15,"is_preprint":false},{"pmid":"31333416","id":"PMC_31333416","title":"Mast Cell/Proteinase Activated Receptor 2 (PAR2) Mediated Interactions in the Pathogenesis of Discogenic Back Pain.","date":"2019","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31333416","citation_count":15,"is_preprint":false},{"pmid":"25468564","id":"PMC_25468564","title":"Per a 10 activates human derived epithelial cell line in a protease dependent manner via PAR-2.","date":"2014","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/25468564","citation_count":15,"is_preprint":false},{"pmid":"26860791","id":"PMC_26860791","title":"Role of PAR2 in the Development of Lower Urinary Tract Dysfunction.","date":"2016","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/26860791","citation_count":15,"is_preprint":false},{"pmid":"33262514","id":"PMC_33262514","title":"Activation of PAR2 by tissue factor induces the release of the PTEN from MAGI proteins and regulates PTEN and Akt activities.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33262514","citation_count":14,"is_preprint":false},{"pmid":"32064449","id":"PMC_32064449","title":"Is There a Trojan Horse to Aggressive Pancreatic Cancer Biology? A Review of the Trypsin-PAR2 Axis to Proliferation, Early Invasion, and Metastasis.","date":"2020","source":"Journal of pancreatic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32064449","citation_count":14,"is_preprint":false},{"pmid":"27994760","id":"PMC_27994760","title":"PAR2 Modulators Derived from GB88.","date":"2016","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27994760","citation_count":13,"is_preprint":false},{"pmid":"26631441","id":"PMC_26631441","title":"Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists.","date":"2015","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26631441","citation_count":13,"is_preprint":false},{"pmid":"30172372","id":"PMC_30172372","title":"Protease-activated receptor 2 (PAR2) upregulates granulocyte colony stimulating factor (G-CSF) expression in breast cancer cells.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30172372","citation_count":12,"is_preprint":false},{"pmid":"37580758","id":"PMC_37580758","title":"Role of the protease-activated receptor-2 (PAR2) in the exacerbation of house dust mite-induced murine allergic lung disease by multi-walled carbon nanotubes.","date":"2023","source":"Particle and fibre toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37580758","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52924,"output_tokens":8172,"usd":0.140676},"stage2":{"model":"claude-opus-4-6","input_tokens":12087,"output_tokens":4525,"usd":0.26034},"total_usd":0.401016,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"PAR2 activation sensitizes TRPA1 channels in DRG neurons via PLC-mediated hydrolysis of plasma membrane PIP2, relieving tonic PIP2 inhibition of TRPA1 and increasing TRPA1 currents; this mechanism contributes to inflammatory pain.\",\n      \"method\": \"Electrophysiology in HEK293 cells transfected with TRPA1 and DRG neurons; PLC inhibitors and antibody sequestration of PIP2; colocalization immunofluorescence\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (electrophysiology, pharmacological inhibition, PIP2 sequestration) in both heterologous and native systems; widely cited\",\n      \"pmids\": [\"17571167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cathepsin S acts as a biased agonist of PAR2 by cleaving at E56↓T57 (distinct from canonical trypsin cleavage at R36↓S37), exposing a novel tethered ligand that selectively couples PAR2 to Gαs/cAMP but not Ca2+ mobilization, β-arrestin recruitment, or ERK1/2 activation; Cat-S–activated PAR2 then stimulates TRPV4 and causes hyperalgesia via adenylyl cyclase/PKA.\",\n      \"method\": \"Cleavage-site mapping; cAMP assay; Ca2+ mobilization assay; β-arrestin recruitment assay; Xenopus oocyte TRPV4 functional assay; PAR2/TRPV4 knockout mice; in vivo paw inflammation model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical cleavage site identification plus multiple functional signaling readouts plus genetic knockout validation in vivo\",\n      \"pmids\": [\"25118282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cathepsin S cleaves PAR2 near the N-terminus to expose a novel tethered ligand sequence KVDGTS; mutation of the cathepsin S cleavage site prevents receptor activation by the protease while the hexapeptide KVDGTS retains PAR2 signaling activity.\",\n      \"method\": \"Protease cleavage assay; site-directed mutagenesis of PAR2 cleavage site; peptide functional assay in cells expressing PAR2\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cleavage-site mapping with mutagenesis and peptide reconstitution\",\n      \"pmids\": [\"24964046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PAR1 and PAR2 form a stable heterodimer that exhibits constitutive internalization driven by PAR1 C-terminal tail sorting motifs; thrombin-activated PAR1-PAR2 heterodimers co-internalize, recruit β-arrestins to endosomes, and enhance cytoplasmic (not nuclear) β-arrestin-mediated ERK1/2 activation.\",\n      \"method\": \"BRET; immunofluorescence microscopy; co-immunoprecipitation; cells expressing receptors exogenously and endogenously; ERK1/2 activation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, BRET, and functional signaling assays; multiple orthogonal methods in one study\",\n      \"pmids\": [\"23476015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PAR2 facilitates plasma membrane delivery of PAR4 by disrupting PAR4's ER-retention complex with β-COP1 and promoting interaction with chaperone 14-3-3ζ; PAR2-PAR4 heterodimerization was confirmed by intermolecular FRET, and PAR2 co-expression enhanced PAR4 glycosylation and signaling.\",\n      \"method\": \"FRET; co-immunoprecipitation; mutagenesis of PAR4 RXR ER-retention sequence; immunofluorescence; glycosylation analysis; signaling assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — structural mutagenesis plus FRET plus biochemical co-IP with multiple readouts\",\n      \"pmids\": [\"22411985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In gastric smooth muscle cells, PAR2 couples to Gq, G13, and Gi1, stimulating PI hydrolysis (via Gαq/Gαi), Rho kinase activation (via Gα13), and biphasic contraction; PAR2-activated RhoA is subject to feedback inhibition via NF-κB–dependent release of PKA catalytic subunit, which phosphorylates RhoA at Ser188.\",\n      \"method\": \"PAR2/Gα siRNA knockdown; Gα minigene expression; pertussis toxin; dominant-negative mutants; Rho kinase activity assay; contractility assay; phospho-immunoblotting\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological perturbations with defined signaling readouts\",\n      \"pmids\": [\"23825105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In colitis, PAR2 redistributes from the basolateral membrane of colonocytes to early endosomes; endosomal PAR2 assembles signaling complexes containing Gαq, Gαi, and β-arrestin; dynamin-2-dependent endocytosis is required for PAR2-evoked colonic inflammation and hyperalgesia.\",\n      \"method\": \"Knockin mice expressing PAR2-muGFP; immunostaining; RNAScope in situ hybridization; confocal microscopy; Dnm2 siRNA knockdown; dynamin inhibitors; cytokine release assays; mouse colitis models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — endogenous fluorescent reporter knockin mice plus genetic knockdown plus functional readouts; strong mechanistic evidence\",\n      \"pmids\": [\"35110404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EPCR-dependent activation of PAR2 by the ternary TF-VIIa-Xa coagulation complex is required for LPS-induced expression of Pellino-1 and IRF8, thereby initiating an interferon-regulated gene expression program; mice lacking EPCR or PAR2 fail to mount this interferon response.\",\n      \"method\": \"Bone marrow-derived myeloid cell cultures; RAW264.7 cells; PAR2/EPCR knockout mice; LPS challenge in vivo; mRNA profiling\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo (dual KO) plus in vitro mechanistic validation\",\n      \"pmids\": [\"25733582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Genetic epistasis in mouse skin demonstrates that PAR2 is a downstream effector of the serine protease CAP1/Prss8: transgenic overexpression of CAP1/Prss8 causes epidermal hyperplasia, ichthyosis, and skin inflammation that is completely abolished on a PAR2-null background.\",\n      \"method\": \"Transgenic mouse models (K14-CAP1/Prss8); PAR2-null background; histology; barrier function assays; cytokine measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic epistasis with complete rescue phenotype in vivo\",\n      \"pmids\": [\"21245842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Activated protein C (aPC) signals through a PAR2/PAR3 heterodimer on regulatory T cells (CD4+FOXP3+) to restrict allogenic T-cell activation and expand Tregs, thereby ameliorating graft-vs.-host disease.\",\n      \"method\": \"PAR2/PAR3 knockout mice; Treg frequency measurement; allogeneic HSC transplantation model; humanized mouse model (NSG-AB°DR4)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion of PAR2 and PAR3 with defined cellular phenotype; validated in humanized mouse model\",\n      \"pmids\": [\"28827518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GPR97 allosterically activates CD177-associated membrane proteinase 3 (mPR3) within a macromolecular CD177/GPR97/PAR2/CD16b complex on neutrophils; mPR3 activation within this complex cleaves and activates PAR2, triggering inflammatory activation, ICAM-1/VCAM-1 upregulation, and endothelial dysfunction.\",\n      \"method\": \"Crystallography of GPR97 extracellular domain; deletion analysis; co-immunoprecipitation; functional neutrophil activation assays; PAR2 activation readouts\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure of binding domain combined with deletion analysis and functional assays\",\n      \"pmids\": [\"36302784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PAR2-induced ovarian cancer cell migration and invasion requires cooperative signaling through Gαq/11, Gα12/13, and β-arrestin1/2 (not Gαs or Gαi), leading to serial activation of Src kinases, EGFR transactivation, and downstream MEK-ERK1/2-FOS/MYC/STAT3-COX2; loss of any single pathway component abolishes motility.\",\n      \"method\": \"CRISPR-Cas9 knockouts of PAR2, Gα proteins, and β-arrestin1/2; pharmacological inhibitors; western blots; migration/invasion assays\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR genetic knockouts combined with pharmacological dissection of each pathway node\",\n      \"pmids\": [\"33226635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Furin is the principal proprotein convertase that cleaves PAR2 at Arg36↓; N-glycosylation of PAR2 at Asn30 reduces the efficiency but enhances selectivity of Furin cleavage; Furin expression enhances neuronal cell viability against PAR2-induced cytotoxicity in the context of HIV-1 infection.\",\n      \"method\": \"In vitro cleavage assays; site-directed mutagenesis of PAR2 (Arg36, Asn30); co-culture of neuroblastoma cells with HIV-1-infected macrophages; PACS1 trafficking studies\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical cleavage assay with mutagenesis; functional validation in neuronal co-culture model\",\n      \"pmids\": [\"30683917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PAR2 deficiency in mice (PAR-2 knockout) prevents PAR1-dependent pro-fibrotic responses in bleomycin-induced pulmonary fibrosis; PAR1 signaling in fibroblasts requires the presence of PAR2, establishing PAR2 as necessary for PAR1-dependent signaling in this context.\",\n      \"method\": \"PAR2-knockout mice; bleomycin lung fibrosis model; fibroblast stimulation with PAR1/PAR2 agonists; PAR1 antagonist (P1pal-12); collagen/SMA western blot; hydroxyproline quantification\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus pharmacological epistasis in vivo and in vitro\",\n      \"pmids\": [\"25689283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The PAR2 inhibitor I-287 acts as a negative allosteric modulator selectively blocking Gαq and Gα12/13 signaling and their downstream effectors while having no effect on Gi/o signaling or β-arrestin2 engagement; selective inhibition of only the Gαq/Gα12/13 pathways is sufficient to block PAR2-driven inflammation in vivo.\",\n      \"method\": \"BRET-based signaling pathway profiling; in vivo inflammatory model; selective PAR2 inhibitor characterization\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multi-pathway BRET profiling plus in vivo validation with defined selectivity\",\n      \"pmids\": [\"33247181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PAR2 activation downregulates the hepatic glucose transporter GLUT2 through a Gq-MAPK-FoxA3 pathway and inhibits insulin-Akt signaling through a Gq-calcium-CaMKK2 pathway, thereby suppressing glucose internalization and glycogen storage; liver-specific PAR2 knockout rescues these defects.\",\n      \"method\": \"Whole-body and liver-specific PAR2-KO mice; mechanistic pathway inhibitors; GLUT2/FoxA3 expression assays; Akt phosphorylation assays; glycogen storage measurements; pepducin therapeutic dosing\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific genetic knockout plus pharmacological dissection of bifurcating signaling pathways\",\n      \"pmids\": [\"35603482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PAR2 deficiency in mice reduces plasma and total liver cholesterol by ~50% through decreased expression of hepatic cholesterol synthesis genes and induction of reverse cholesterol transport; Gi-Jnk1/2 signaling downstream of PAR2 was identified as the key effector pathway regulating lipid and cholesterol homeostasis in liver.\",\n      \"method\": \"PAR2-KO mice (C57BL/6 F2rl1-/-); normal/high-fat diet feeding; plasma/liver lipid assays; hepatic gene expression; fecal bile acid output; pathway inhibitor studies\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with multi-parameter metabolic phenotyping and pathway identification\",\n      \"pmids\": [\"31668396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PAR2 expression is required for TGF-β1-induced ERK1/2 activation (but not SMAD activation) and cell migration; PAR2 physically interacts with ALK5 (TGF-β type I receptor) as shown by co-immunoprecipitation, and ERK inhibition abolishes PAR2-AP- and TGF-β1-induced migration.\",\n      \"method\": \"siRNA depletion of PAR2; xCELLigence cell migration assay; phospho-immunoblotting for ERK1/2 and SMAD; co-immunoprecipitation of PAR2 with ALK5; MEK inhibitor U0126\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP interaction plus siRNA knockdown with functional migration readout; single lab\",\n      \"pmids\": [\"29261154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TF/FVIIa complex mediates vascular smooth muscle cell migration via PAR2; PAR2-activating peptide SLIGKV (but not PAR1-AP or PAR4-AP) stimulates SMC migration comparable to TF/FVIIa, and anti-PAR2-AP antisera blocks TF/FVIIa-induced migration.\",\n      \"method\": \"Modified Boyden chamber migration assay; PAR2-activating peptide; neutralizing antisera; immunostaining of human coronary arteries\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional migration assay with pharmacological blockade; single lab\",\n      \"pmids\": [\"12479889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PAR2 triggers IL-8 release from GI epithelial cells via two independent, non-overlapping signaling pathways: MEK/ERK and PI3-kinase/Akt; inhibition of MEK blocks ERK but not Akt phosphorylation, and vice versa.\",\n      \"method\": \"PAR2-activating peptide stimulation; MEK inhibitor U0126; PI3K inhibitor LY294002; ERK and Akt phosphorylation by immunoblot; IL-8 ELISA\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological pathway dissection with dual independent signaling readouts\",\n      \"pmids\": [\"18854173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PAR2 activation reduces cytokine-induced epithelial apoptosis via concurrent stimulation of MEK1/2 (leading to BAD phosphorylation at Ser112) and PI3K (leading to BAD phosphorylation at Ser136); simultaneous inhibition of both pathways is required to abolish the anti-apoptotic effect; PAR2 siRNA knockdown eliminates this protection.\",\n      \"method\": \"Caspase-3/8/9 cleavage assays; PARP cleavage; annexin V staining; siRNA knockdown of PAR2, BAD, MCL-1; MEK and PI3K inhibitors; phospho-BAD immunoblotting\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown plus pharmacological dissection of two convergent pathways with multiple apoptosis readouts\",\n      \"pmids\": [\"25331954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PAR2-induced TRPV4 channel activation is dependent on tyrosine kinases and PI3K but not Gαq or store-operated calcium entry (thapsigargin-insensitive); the tyrosine kinase inhibitor bafetinib, but not dasatinib, blocks PAR2-induced TRPV4 gating and mechanical hyperalgesia in vivo.\",\n      \"method\": \"Calcium imaging in HEK293 cells; TRPV4 transfection; pharmacological inhibitors; in vivo mechanical hyperalgesia assay\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — heterologous expression plus in vivo pharmacological validation; single lab\",\n      \"pmids\": [\"24779362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PAR2 activation promotes M1-like macrophage polarization and proinflammatory cytokine expression through a FOXO1-dependent pathway; FOXO1 nuclear accumulation is required for PAR2-induced transcription of IL-1β, IL-6, MCP-1, and TNF-α, and FOXO1 siRNA knockdown abolishes this effect.\",\n      \"method\": \"Bone marrow-derived macrophages; PAR2 agonist stimulation; transcription factor microarray; qRT-PCR; western blot; immunofluorescence for FOXO1 localization; siRNA knockdown of FOXO1\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple methods but single lab; siRNA rescue validates pathway\",\n      \"pmids\": [\"30552714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Plasma kallikrein modulates blood-brain barrier integrity via PAR2 on endothelial cells, leading to upregulation of ICAM-1 and VCAM-1 and amplified leukocyte trafficking; prekallikrein deficiency or blockade reduces BBB disruption and CNS inflammation in experimental autoimmune encephalomyelitis.\",\n      \"method\": \"In vitro endothelial cell PAR2 activation; ICAM-1/VCAM-1 upregulation assays; prekallikrein-deficient mice; EAE model; leukocyte trafficking quantification\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vitro mechanistic assay plus genetic model in vivo; single lab\",\n      \"pmids\": [\"30559188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Kallikrein 6 (Klk6) signals through both PAR1 and PAR2 to activate ERK1/2 in neurons via phosphoinositide 3-kinase and MEK-dependent pathways, exacerbating glutamate neurotoxicity; lipopeptide inhibitors of PAR1 or PAR2, and PAR1 genetic deletion, each reduce Klk6-ERK1/2 activation.\",\n      \"method\": \"Recombinant Klk6 treatment of cerebellar granule neurons and NSC34 cells; PAR1/PAR2 lipopeptide inhibitors; PAR1 knockout mice; ERK1/2 activation assays; LDH/caspase assays\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological and genetic epistasis with multiple neuronal readouts; single lab\",\n      \"pmids\": [\"23647384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PAR2 activation by tissue factor releases PTEN from its MAGI1-3 protein complex (demonstrated by proximity ligation assay and co-IP), transiently increasing PTEN lipid phosphatase activity and reducing Akt activity; prolonged TF exposure reduces PTEN antigen levels with concurrent Akt activation and increased proliferation.\",\n      \"method\": \"Proximity ligation assay; co-immunoprecipitation; PTEN/Akt phosphorylation assays; PAR2-agonist peptide; recombinant TF treatment; seven cancer cell lines\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — PLA and co-IP with functional kinase activity assays; single lab, multiple cell lines\",\n      \"pmids\": [\"33262514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Mast cell tryptase promotes profibrotic phenotype in atrial fibroblasts via PAR2 and PPARγ pathways; the PAR2 antagonist FSLLRY-NH2 or PPARγ antagonist GW9662 abolishes tryptase-induced collagen I, fibronectin, laminin accumulation, and MMP upregulation.\",\n      \"method\": \"Primary atrial fibroblast culture; tryptase treatment; PAR2 antagonist; PPARγ antagonist; collagen/fibronectin/MMP western blots; cell proliferation and migration assays\",\n      \"journal\": \"Archives of medical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological antagonism with fibrotic readouts; single lab\",\n      \"pmids\": [\"30580879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PAR2 activation in renal tubular epithelial cells induces chemokine (MCP1, MCP3) upregulation via the MAPK-NF-κB signaling pathway, driving inflammatory cell recruitment; PAR2-knockout mice are protected from adenine diet-induced renal fibrosis and inflammation.\",\n      \"method\": \"PAR2-knockout mice; adenine diet model; NRK52E epithelial cells; PAR2 agonist; MAPK and NF-κB inhibitors; qRT-PCR for chemokines; macrophage migration assay\",\n      \"journal\": \"Archives of pharmacal research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic KO with in vitro pathway dissection; single lab\",\n      \"pmids\": [\"35334088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PAR2 deficiency in MDSCs directly enhances their immunosuppressive activity through STAT3-mediated reactive oxygen species production, reshaping the tumor microenvironment to promote colorectal tumorigenesis.\",\n      \"method\": \"PAR2-KO mice; AOM/DSS colitis-associated cancer model; flow cytometry for MDSC/macrophage/T-cell infiltration; STAT3 pathway analysis; ROS measurement\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic KO with defined cellular phenotype and pathway identification; single lab\",\n      \"pmids\": [\"31733286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PAR2 pepducin PZ-235, designed to mimic the juxtamembrane helical region of TM6/third intracellular loop, forms a well-structured α-helix and blocks PAR2-mediated reactive oxygen species production in hepatocytes and stellate cell activation, suppressing liver fibrosis, collagen deposition, and inflammation.\",\n      \"method\": \"NMR structure of PZ-235 peptide; mouse CCl4 and MCD diet fibrosis models; pepducin treatment; stellate cell activation assays; ROS assay; histology; collagen quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — NMR structural characterization of pepducin plus in vivo therapeutic validation\",\n      \"pmids\": [\"27613872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PAR2 activation causes migraine-like pain behaviors (facial grimace and mechanical allodynia) upon dural application in mice; functional PAR2 is expressed on trigeminal neurons and dural fibroblasts; the effect is attenuated by PAR2 antagonist C391 and is absent in PAR2-/- mice.\",\n      \"method\": \"Ca2+ imaging of trigeminal neurons and dural fibroblasts; behavioral assays (grimace scale, von Frey); PAR2-KO mice; PAR2 antagonist C391; sumatriptan comparison\",\n      \"journal\": \"Cephalalgia : an international journal of headache\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus pharmacological antagonism with defined behavioral phenotype\",\n      \"pmids\": [\"29848111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In differentiated human keratinocytes, PAR2-evoked Ca2+ store depletion and downstream inflammatory mediator production (IL-1β, TNF-α, TSLP) require both InsP3R and TRPV1 in intracellular Ca2+ stores, rather than ORAI1-mediated store-operated Ca2+ entry; PLC inhibition abolishes these responses.\",\n      \"method\": \"Ca2+ imaging; TRPV1/InsP3R/ORAI1 inhibitors; NF-κB activity assay; cytokine ELISA; PAR2-activating peptide SLIGKV in primary keratinocytes\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological dissection with multiple readouts in primary human cells; single lab\",\n      \"pmids\": [\"29458120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MicroRNA-34a mediates PAR2-induced upregulation of Cyclin D1 in colon cancer cells; TGF-β contributes to PAR2 regulation of miR-34a; PAR2 knockdown or inactivation of its autocrine activating proteinase reduces proliferation in vitro and tumorigenicity in vivo.\",\n      \"method\": \"siRNA knockdown of PAR2; miR-34a inhibitor; Cyclin D1 expression; in vitro proliferation; xenograft mouse model; TGF-β pathway analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — siRNA plus in vivo xenograft model with miRNA mechanistic link\",\n      \"pmids\": [\"23991105\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PAR2 (F2RL1) is a G protein-coupled receptor activated by serine proteases (trypsin, tryptase, coagulation factors VIIa/Xa) and cysteine proteases (cathepsin S) that cleave its N-terminus to unmask a tethered ligand; it signals through multiple G proteins (Gαq, Gα12/13, Gαi, Gαs) and β-arrestins to regulate TRPA1/TRPV4 sensitization (via PLC-PIP2), ERK1/2 activation, NF-κB, RhoA/Rho kinase, PI3K/Akt, and cAMP/PKA pathways; it forms heterodimers with PAR1, PAR3, and PAR4 that alter trafficking and signaling; endocytosis-dependent endosomal signaling complexes sustain inflammatory and nociceptive responses; and PAR2 plays defined roles in neurogenic inflammation and pain, skin barrier homeostasis, liver glucose and lipid metabolism, pulmonary and hepatic fibrosis, and immune regulation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"F2RL1 (PAR2) is a protease-activated G protein-coupled receptor that transduces extracellular proteolytic signals into diverse intracellular cascades governing inflammation, pain, tissue remodeling, and metabolic homeostasis. Serine proteases (trypsin, tryptase, coagulation factors VIIa/Xa, kallikrein 6, proteinase 3, CAP1/Prss8) and the cysteine protease cathepsin S cleave the PAR2 N-terminus at distinct sites to unmask different tethered ligands, producing biased signaling: canonical cleavage at Arg36 activates Gαq/Gα12/13/Gαi and β-arrestin pathways driving PLC–PIP2 hydrolysis, RhoA/Rho kinase, MEK–ERK1/2, PI3K–Akt, and NF-κB, whereas cathepsin S cleavage at Glu56 selectively engages Gαs/cAMP/PKA to sensitize TRPV4 channels [PMID:17571167, PMID:25118282, PMID:23825105, PMID:33226635]. PAR2 forms functional heterodimers with PAR1, PAR3, and PAR4 that alter receptor trafficking, β-arrestin–mediated endosomal ERK signaling, and immune regulation—including activated protein C–driven Treg expansion via PAR2/PAR3 heterodimers—and dynamin-2-dependent endocytosis sustains PAR2 endosomal signaling complexes required for colonic inflammation and hyperalgesia [PMID:23476015, PMID:22411985, PMID:28827518, PMID:35110404]. In metabolic tissues, hepatic PAR2 suppresses glucose uptake through Gq–MAPK–FoxA3-dependent GLUT2 downregulation and Gq–CaMKK2-mediated inhibition of insulin–Akt signaling, while PAR2–Gi–JNK1/2 signaling regulates cholesterol synthesis and reverse cholesterol transport [PMID:35603482, PMID:31668396].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying TF/FVIIa as a PAR2 ligand in vascular cells established that coagulation proteases drive PAR2-dependent cell migration, linking hemostasis to vascular remodeling.\",\n      \"evidence\": \"Boyden chamber migration assay with PAR2-activating peptide and neutralizing antisera in smooth muscle cells\",\n      \"pmids\": [\"12479889\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream signaling pathway not dissected\", \"Single cell type tested\", \"No genetic confirmation\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating that PAR2 sensitizes TRPA1 through PLC-mediated PIP2 hydrolysis resolved how protease signaling couples to nociceptive ion channels and provided a molecular mechanism for inflammatory pain.\",\n      \"evidence\": \"Electrophysiology in HEK293 cells and DRG neurons with PLC inhibitors and PIP2 antibody sequestration\",\n      \"pmids\": [\"17571167\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo behavioral validation of PIP2 mechanism not shown in this study\", \"Whether TRPV1 is co-regulated by the same mechanism unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of two independent, non-overlapping PAR2 signaling branches—MEK/ERK and PI3K/Akt—converging on IL-8 release revealed how PAR2 achieves robust inflammatory cytokine output through pathway redundancy.\",\n      \"evidence\": \"Pharmacological inhibition of MEK and PI3K with phospho-protein and cytokine readouts in GI epithelial cells\",\n      \"pmids\": [\"18854173\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic knockdown confirmation\", \"G protein coupling to each branch not identified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Genetic epistasis showing that the skin pathology of CAP1/Prss8 overexpression is completely abolished on a PAR2-null background established PAR2 as the obligate downstream effector of this protease in epidermal homeostasis.\",\n      \"evidence\": \"Transgenic K14-CAP1/Prss8 mice crossed to PAR2-null background; histology, barrier function, and cytokine assays\",\n      \"pmids\": [\"21245842\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct cleavage of PAR2 by CAP1/Prss8 not biochemically demonstrated\", \"Downstream PAR2 signaling pathway in keratinocytes not identified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovery that PAR2 promotes PAR4 plasma membrane delivery by disrupting β-COP1-mediated ER retention and recruiting 14-3-3ζ revealed PAR2's role as a chaperone for other PARs, expanding the concept of GPCR heterodimerization beyond co-signaling to trafficking control.\",\n      \"evidence\": \"FRET, co-immunoprecipitation, mutagenesis of PAR4 RXR ER-retention motif, glycosylation and signaling assays\",\n      \"pmids\": [\"22411985\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PAR2 similarly chaperones PAR3 unknown\", \"Structural basis of PAR2-PAR4 interface not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Characterization of PAR1–PAR2 heterodimer constitutive internalization and endosomal β-arrestin–ERK signaling, together with the finding that PAR2 couples to Gq/G13/Gi with RhoA feedback inhibition via NF-κB–PKA in smooth muscle, defined how heterodimerization and G protein multiplicity shape PAR2 signaling output.\",\n      \"evidence\": \"BRET, co-IP, and ERK assays for PAR1–PAR2 heterodimers; siRNA/minigene/pertussis toxin dissection in gastric smooth muscle\",\n      \"pmids\": [\"23476015\", \"23825105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural determinants of PAR1–PAR2 heterodimerization interface not defined\", \"Whether RhoA–PKA feedback operates outside smooth muscle untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of cathepsin S as a biased agonist cleaving PAR2 at a non-canonical site (Glu56↓Thr57) to selectively engage Gαs/cAMP without β-arrestin or Ca²⁺ mobilization fundamentally changed the model of PAR2 activation from a single tethered-ligand mechanism to protease-specific biased agonism.\",\n      \"evidence\": \"Cleavage-site mapping, cAMP/Ca²⁺/β-arrestin assays, TRPV4 functional assay in oocytes, PAR2/TRPV4 KO mice\",\n      \"pmids\": [\"25118282\", \"24964046\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other cysteine proteases produce similar bias unknown\", \"Structural basis for bias at receptor level not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstration that PAR2 protects epithelial cells from cytokine-induced apoptosis through convergent MEK–BAD(Ser112) and PI3K–BAD(Ser136) phosphorylation established a cytoprotective function for PAR2 and explained why both pathways must be inhibited simultaneously to block survival signaling.\",\n      \"evidence\": \"Caspase/PARP cleavage, annexin V, phospho-BAD immunoblotting, PAR2 siRNA, MEK/PI3K inhibitors\",\n      \"pmids\": [\"25331954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream G protein coupling to each survival branch not identified\", \"In vivo relevance of anti-apoptotic function not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Two studies established PAR2 as a critical mediator in fibrosis and innate immunity: PAR2 was shown to be required for PAR1-dependent pulmonary fibrosis, and EPCR-dependent PAR2 activation by the TF–VIIa–Xa complex was found to initiate an interferon gene program via Pellino-1/IRF8.\",\n      \"evidence\": \"PAR2-KO mice in bleomycin fibrosis model; PAR2/EPCR-KO mice with LPS challenge and mRNA profiling\",\n      \"pmids\": [\"25689283\", \"25733582\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PAR1–PAR2 heterodimerization is the mechanism underlying PAR2 requirement in fibrosis not directly tested\", \"How EPCR scaffolding alters PAR2 cleavage specificity unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Discovery that activated protein C signals through PAR2/PAR3 heterodimers on Tregs to restrain alloreactive T cells and ameliorate graft-versus-host disease linked PAR2 to adaptive immune regulation and established a non-inflammatory, immunosuppressive role for PAR2.\",\n      \"evidence\": \"PAR2/PAR3-KO mice; allogeneic HSCT model; humanized NSG mouse model; Treg frequency analysis\",\n      \"pmids\": [\"28827518\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathway in Tregs not dissected\", \"Whether aPC-PAR2/PAR3 axis operates in solid organ transplant tolerance unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Multiple studies in 2018 expanded PAR2's tissue-specific roles: plasma kallikrein activates PAR2 to disrupt the blood-brain barrier via ICAM-1/VCAM-1; PAR2 drives FOXO1-dependent M1 macrophage polarization; mast cell tryptase signals through PAR2–PPARγ to promote atrial fibrosis; and PAR2 on trigeminal neurons mediates migraine-like pain.\",\n      \"evidence\": \"Endothelial PAR2 activation with prekallikrein-KO EAE model; macrophage FOXO1 siRNA; atrial fibroblast PAR2/PPARγ antagonism; dural PAR2-KO mice with behavioral pain assays\",\n      \"pmids\": [\"30559188\", \"30552714\", \"30580879\", \"29848111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Integration of these tissue-specific findings into a unified signaling framework lacking\", \"Whether migraine mechanism involves endosomal PAR2 signaling unknown\", \"PPARγ link to canonical PAR2 G protein pathways not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of furin as the principal proprotein convertase processing PAR2 at Arg36, modulated by N-glycosylation at Asn30, revealed a post-translational regulatory layer controlling PAR2 activation efficiency and selectivity, with functional consequences in HIV-1-associated neurotoxicity.\",\n      \"evidence\": \"In vitro cleavage assays with site-directed mutagenesis; neuroblastoma-macrophage co-culture with HIV-1\",\n      \"pmids\": [\"30683917\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether furin activates PAR2 in trans at the cell surface or in the secretory pathway not distinguished\", \"Relevance of this processing to other PAR2 disease contexts untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstration that PAR2-KO mice have ~50% reduced plasma and hepatic cholesterol via decreased synthesis genes and increased reverse cholesterol transport, mediated by Gi–JNK1/2 signaling, established PAR2 as a metabolic regulator of cholesterol homeostasis.\",\n      \"evidence\": \"PAR2-KO mice on normal and high-fat diets; plasma/liver lipid profiling; fecal bile acid output; pathway inhibitors\",\n      \"pmids\": [\"31668396\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether hepatocyte-specific or systemic PAR2 deletion is responsible not resolved\", \"Identity of the endogenous activating protease in metabolic context unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"CRISPR-based dissection of PAR2 signaling in ovarian cancer revealed that migration/invasion absolutely requires cooperative Gαq/11, Gα12/13, and β-arrestin1/2 engagement driving Src–EGFR transactivation–MEK–ERK–transcription factor cascades, while a negative allosteric modulator selectively blocking Gαq/Gα12/13 was sufficient to suppress inflammation in vivo.\",\n      \"evidence\": \"CRISPR-KO of individual G proteins and β-arrestins in cancer cells; BRET signaling profiling of PAR2 inhibitor I-287; in vivo inflammation model\",\n      \"pmids\": [\"33226635\", \"33247181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether pathway cooperativity requirement is cancer-type specific untested\", \"Structural basis for allosteric modulator selectivity not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Three 2022 studies completed the picture of PAR2 compartmentalized signaling and metabolic function: endosomal PAR2 assemblies (Gαq/Gαi/β-arrestin) in colonocytes sustain colitis; GPR97 allosterically activates mPR3 within a CD177/GPR97/PAR2/CD16b neutrophil complex; and liver-specific PAR2-KO rescues glucose/glycogen defects by restoring GLUT2 and insulin-Akt signaling.\",\n      \"evidence\": \"PAR2-muGFP knockin mice with dynamin inhibition in colitis; GPR97 crystal structure with co-IP and neutrophil activation; liver-specific PAR2-KO with pepducin treatment and metabolic phenotyping\",\n      \"pmids\": [\"35110404\", \"36302784\", \"35603482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How endosomal vs. surface PAR2 signals are decoded differently at the transcriptional level unknown\", \"Whether CD177/GPR97/PAR2 complex exists outside neutrophils not tested\", \"Identity of endogenous hepatic PAR2 activating protease still unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include the identity of endogenous PAR2-activating proteases in hepatic metabolic regulation, the structural basis for protease-specific biased agonism at the receptor level, how endosomal versus surface PAR2 signals are differentially decoded, and whether PAR2 heterodimer combinations produce distinct functional outcomes across additional tissue contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution PAR2 structure in complex with tethered ligand variants\", \"Endogenous protease activating hepatic PAR2 unknown\", \"Systematic comparison of heterodimer signaling profiles lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 5, 6, 11, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 9, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 6, 10, 11]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 5, 6, 11, 14, 15, 16]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 9, 22, 23, 28]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [7, 18]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [0, 1, 30]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [15, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"complexes\": [\n      \"PAR1-PAR2 heterodimer\",\n      \"PAR2-PAR3 heterodimer\",\n      \"PAR2-PAR4 heterodimer\",\n      \"CD177/GPR97/PAR2/CD16b complex\"\n    ],\n    \"partners\": [\n      \"F2R\",\n      \"F2RL2\",\n      \"F2RL3\",\n      \"TRPA1\",\n      \"TRPV4\",\n      \"PROCR\",\n      \"ADGRF5\",\n      \"TGFBR1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}